| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.2147/AHMT.S50015 |
| P8608 | Fatcat ID | release_e56xmboobnabdemz6mv5cax64i |
| P932 | PMC publication ID | 4250023 |
| P698 | PubMed publication ID | 25473324 |
| P5875 | ResearchGate publication ID | 269188370 |
| P50 | author | Eiji Kirino | Q78003881 |
| P2093 | author name string | Eiji Kirino | |
| P2860 | cites work | Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder | Q22242775 |
| Aripiprazole alone or in combination for acute mania | Q24201765 | ||
| Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children | Q24564288 | ||
| Meta-analysis of epidemiologic studies of pediatric bipolar disorder | Q28240676 | ||
| National trends in the outpatient diagnosis and treatment of bipolar disorder in youth | Q28244462 | ||
| 5-HT2C receptor activation decreases appetite and body weight in obese subjects | Q28253985 | ||
| Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report | Q28291786 | ||
| Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells | Q28327349 | ||
| Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). | Q30925648 | ||
| Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data | Q33532260 | ||
| H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. | Q33964839 | ||
| Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. | Q33966353 | ||
| Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles | Q34006864 | ||
| Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder | Q34020344 | ||
| Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies | Q34183320 | ||
| Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis | Q34200326 | ||
| A functional genetic variation of the 5-HT2a receptor affects human memory | Q34270895 | ||
| Clinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorder | Q34332307 | ||
| Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. | Q34375654 | ||
| Partial dopamine agonists in the treatment of psychosis | Q34603506 | ||
| Focus on aripiprazole: a review of its use in child and adolescent psychiatry | Q34611306 | ||
| Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents | Q34613195 | ||
| Youth meeting symptom and impairment criteria for mania-like episodes lasting less than four days: an epidemiological enquiry | Q34866613 | ||
| Aripiprazole: profile on efficacy and safety | Q35020547 | ||
| Serotonin receptors: their key role in drugs to treat schizophrenia | Q35595261 | ||
| The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice | Q35631475 | ||
| The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review | Q36015766 | ||
| Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review. | Q36026701 | ||
| The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics | Q45340132 | ||
| Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study | Q45829770 | ||
| Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone | Q46380164 | ||
| A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia | Q46395528 | ||
| Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial | Q46681464 | ||
| Clinical correlates and familial aggregation of age at onset in bipolar disorder | Q46921509 | ||
| Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia | Q46969578 | ||
| Olanzapine versus placebo in the treatment of adolescents with bipolar mania | Q46979845 | ||
| Aripiprazole in the treatment of irritability associated with autistic disorder in paediatric patients: profile report. | Q50309492 | ||
| Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents. | Q50786612 | ||
| Quality of life in pediatric bipolar disorder. | Q51871773 | ||
| An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics | Q68314019 | ||
| Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study | Q86199031 | ||
| Treatment guidelines for children and adolescents with bipolar disorder | Q36052032 | ||
| Efficacy and safety of aripiprazole in child and adolescent patients | Q36075828 | ||
| The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders | Q36321595 | ||
| Bipolar disorder in children and adolescents: international perspective on epidemiology and phenomenology | Q36364799 | ||
| A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents | Q36635790 | ||
| Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice | Q36759748 | ||
| Prolactin serum concentrations during aripiprazole treatment in youth | Q36853126 | ||
| Aripiprazole: in adolescents with schizophrenia | Q37021245 | ||
| Comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability | Q37155306 | ||
| The use of atypical antipsychotics in pediatric bipolar disorder. | Q37183419 | ||
| Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents | Q37183426 | ||
| Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change | Q37244631 | ||
| Phenomenology, socio-demographic factors and outcome upon discharge of manic and mixed episodes in hospitalized adolescents: a chart review | Q37364460 | ||
| Utility of atypical antipsychotics in the treatment of resistant unipolar depression | Q37488164 | ||
| Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons | Q37779387 | ||
| The bipolar spectrum: myth or reality? | Q37790651 | ||
| Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients | Q37866291 | ||
| Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review | Q37992396 | ||
| Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal | Q38149091 | ||
| Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study | Q38377712 | ||
| Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial | Q38382241 | ||
| A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder | Q38436733 | ||
| An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. | Q40176997 | ||
| Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic | Q40422380 | ||
| Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia | Q40872011 | ||
| ECG parameters in children and adolescents treated with aripiprazole and risperidone. | Q42627230 | ||
| The health care crisis of childhood-onset bipolar illness: some recommendations for its amelioration. | Q42678459 | ||
| Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study | Q43258937 | ||
| A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder | Q43268278 | ||
| An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder | Q43287181 | ||
| Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. | Q43847484 | ||
| A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania | Q44168457 | ||
| The effects of novel antipsychotics on glucose and lipid levels. | Q44204804 | ||
| Early age at onset as a risk factor for poor outcome of bipolar disorder | Q44295348 | ||
| Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder | Q44513113 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| The poor prognosis of childhood-onset bipolar disorder | Q44620166 | ||
| A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania | Q44684784 | ||
| Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience | Q44848477 | ||
| Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile | Q45052998 | ||
| Atypical antipsychotics: matching receptor profile to individual patient's clinical profile | Q45099748 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | bipolar disorder | Q131755 |
| teenager | Q1492760 | ||
| P304 | page(s) | 211-221 | |
| P577 | publication date | 2014-11-27 | |
| P1433 | published in | Adolescent Health, Medicine and Therapeutics | Q15816528 |
| P1476 | title | Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents | |
| P478 | volume | 5 |
| Q38574425 | Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis |
| Q42371898 | Clinical Usefulness of Aripiprazole and Lamotrigine in Schizoaffective Presentation of Tuberous Sclerosis |
| Q38677949 | Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity |
| Q47284608 | Putative mechanisms of action and clinical use of lithium in children and adolescents: a critical review. |
Search more.